With the idea of seeing how Hanger Orthopedic (NYSE:HGR) and its ACP can add to the overall company, they're going to run the two separately in order to measure their contribution to the overall whole.
Initially it'll last from a range of 6 months to up to a year.
Kaufman likes the idea, and raised their price target on Hanger Orthopedic.
Those running ACP believe they can reach as many as 50 buildings a month in 2011.
Hanger closed Monday at an even $20, up by $0.50, or 2.56 percent. Kaufman raised their price target on them from $22 to $25.
Showing posts with label Hanger Orthopedic Group. Show all posts
Showing posts with label Hanger Orthopedic Group. Show all posts
Tuesday, December 7, 2010
Tuesday, November 23, 2010
Buy Hanger Orthopedic, (NYSE:HGR), BioScrip (Nasdaq:BIOS) Quick Says Noble
Noble Financial says the strongly recommend traders to invest in Hanger Orthopedic Group (NYSE:HGR) and BioScrip, Inc (Nasdaq:BIOS) before the end of the year, citing strong earning potential for Hanger and BioScrip probably trading at a bottom.
Noble said, "We encourage investors to consider Hanger Orthopedic Group (NYSE:HGR) and BioScrip, Inc (Nasdaq:BIOS) for investment before the end of the year...Hanger Orthopedic, while still trading within 7% of its 52 week highs, is currently in the process of refinancing its debt and closing on its Accelerated Care Plus transaction (expected 12/1)...While unknowns remain regarding both the refinancing and the ACP deal, we suspect that the company will be able to generate 2011 EPS well above $1.45 (consensus estimate) and $1.52 (our estimate)."
"BioScrip, unlike Hanger, is well off its 52 week highs (by over 55%) and may experience some tax loss selling over the next 2 to 4 weeks; that said, we believe downside is minimal from current levels. BioScrip is currently undergoing a "strategic assessment" and will disclose its findings in January; we believe shares are trading at a near maximum level of skepticism and urge purchase of BIOS now."
"We think that purchase of HGR and BIOS shares in late 2010 at current
levels could contribute to making 2011 a very happy and profitable new
year."
Hanger closed Monday at $18.69, gaining slightly by $0.02, or 0.11 percent. BioScrip closed at $4.26, remaining the same.
Noble said, "We encourage investors to consider Hanger Orthopedic Group (NYSE:HGR) and BioScrip, Inc (Nasdaq:BIOS) for investment before the end of the year...Hanger Orthopedic, while still trading within 7% of its 52 week highs, is currently in the process of refinancing its debt and closing on its Accelerated Care Plus transaction (expected 12/1)...While unknowns remain regarding both the refinancing and the ACP deal, we suspect that the company will be able to generate 2011 EPS well above $1.45 (consensus estimate) and $1.52 (our estimate)."
"BioScrip, unlike Hanger, is well off its 52 week highs (by over 55%) and may experience some tax loss selling over the next 2 to 4 weeks; that said, we believe downside is minimal from current levels. BioScrip is currently undergoing a "strategic assessment" and will disclose its findings in January; we believe shares are trading at a near maximum level of skepticism and urge purchase of BIOS now."
"We think that purchase of HGR and BIOS shares in late 2010 at current
levels could contribute to making 2011 a very happy and profitable new
year."
Hanger closed Monday at $18.69, gaining slightly by $0.02, or 0.11 percent. BioScrip closed at $4.26, remaining the same.
Subscribe to:
Posts (Atom)